Karch, André

[["dc.bibliographiccitation.firstpage","1013"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Journal of Neurochemistry"],["dc.bibliographiccitation.lastpage","1023"],["dc.bibliographiccitation.volume","129"],["dc.contributor.author","Liman, Jan"],["dc.contributor.author","Deeg, S."],["dc.contributor.author","Voigt, A."],["dc.contributor.author","Voßfeldt, H."],["dc.contributor.author","Dohm, C. P."],["dc.contributor.author","Karch, A."],["dc.contributor.author","Weishaupt, Jochen"],["dc.contributor.author","Schulz, J. B."],["dc.contributor.author","Bähr, M."],["dc.contributor.author","Kermer, P."],["dc.date.accessioned","2017-09-07T11:46:13Z"],["dc.date.available","2017-09-07T11:46:13Z"],["dc.date.issued","2014"],["dc.description.abstract","Spinocerebellar ataxia type 3 (SCA3) is one of at least nine inherited neurodegenerative diseases caused by an expansion of a polyglutamine tract within corresponding disease-specific proteins. In case of SCA3, mutation of Ataxin-3 results in aggregation of misfolded protein, formation of intranuclear as well as cytosolic inclusion bodies and cell death in distinct neuronal populations. Since cyclin-dependent kinase-5 (CDK5) has been shown to exert beneficial effects on aggregate formation and cell death in various polyglutamine diseases, we tested its therapeutic potential for SCA3. Our data show increased caspase-dependent Ataxin-3 cleavage, aggregation, and neurodegeneration in the absence of sufficient CDK5 activity. This disease-propagating effect could be reversed by mutation of the caspase cleavage site in Ataxin-3. Moreover, reduction of CDK5 expression levels by RNAi in vivo enhances SCA3 toxicity as assayed in a Drosophila model for SCA3. In summary, we present CDK5 as a potent neuroprotectant, regulating cleavage and thereby toxicity of Ataxin-3 and other polyglutamine proteins. We propose that increased caspase-dependent cleavage of mutated Ataxin-3, because of missing CDK5 shielding, leads to aggregation and cell death. Moreover, reduction of CDK5 expression levels by RNAi in vivo enhances SCA3 toxicity as assayed in a Drosophila model for SCA3. We think that CDK5 functions as a shield against cleavage-induced toxification and thereby is an interesting target for therapeutic intervention in polyQ disease in general."],["dc.identifier.doi","10.1111/jnc.12684"],["dc.identifier.gro","3142111"],["dc.identifier.isi","000337760500011"],["dc.identifier.pmid","24548080"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/4666"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1471-4159"],["dc.relation.issn","0022-3042"],["dc.title","CDK5 protects from caspase-induced Ataxin-3 cleavage and neurodegeneration"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","163"],["dc.bibliographiccitation.journal","BMC Neurology"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Wasser, Katrin"],["dc.contributor.author","Karch, André"],["dc.contributor.author","Gröschel, Sonja"],["dc.contributor.author","Witzenhausen, Janin"],["dc.contributor.author","Gröschel, Klaus"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Liman, Jan"],["dc.date.accessioned","2017-09-07T11:47:04Z"],["dc.date.available","2017-09-07T11:47:04Z"],["dc.date.issued","2013"],["dc.description.abstract","Background: In-stent restenosis (ISR) is an important factor endangering the long-term safety and efficacy of carotid artery angioplasty and stenting (CAS). It is plausible that soft vulnerable plaques are more likely to be injured during CAS procedure and are therefore more likely to initiate the cascade finally leading to ISR. The aim of this study was to investigate if plaque morphology detected by a simple applicable Duplex ultrasound score before CAS can be used as a predictor for ISR. Methods: Within a prospectively collected single-centre CAS database of 281 patients (comprising 300 arteries) with high-grade carotid artery stenosis, who underwent CAS between May 2003 and January 2013, we conducted a nested case-control study. Plaque morphology before CAS was analysed by a blinded investigator and each parameter of the Total Plaque Risk Score (TPRS) as well as the whole score was evaluated with regard to its diagnostic validity for ISR. Results: We analysed the data of 10 patients with ISR and 50 patients without ISR. There were no significant differences with respect to baseline characteristics, vascular risk factors, and degree of stenosis between patients with and without ISR. The duration of follow-up was longer in patients with ISR (p = 0.024) and these patients were more likely to show increased PSV (p = 0.012) immediately after CAS than patients without ISR. Neither individual parameters of the TPRS score nor the score as a whole were suitable as a diagnostic test for ISR development. Conclusions: In the present study we could demonstrate that the non-contrast enhanced DUS of the pre-interventional plaque formation cannot be used as a predictor for the development of ISR. Evaluating a more sophisticated, but not routinely available approach e. g. by ultrasound based plaque perfusion imaging or CT based plaque analysis could be helpful in the future in order to assess the role of plaque morphology in the context of ISR development."],["dc.identifier.doi","10.1186/1471-2377-13-163"],["dc.identifier.gro","3142254"],["dc.identifier.isi","000329060500003"],["dc.identifier.pmid","24191865"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/9475"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/6243"],["dc.language.iso","en"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.issn","1471-2377"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Plaque morphology detected with Duplex ultrasound before carotid angioplasty and stenting (CAS) is not a predictor of carotid artery in-stent restenosis, a case control study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","73"],["dc.bibliographiccitation.journal","Journal of Clinical Epidemiology"],["dc.bibliographiccitation.lastpage","82"],["dc.bibliographiccitation.volume","78"],["dc.contributor.author","Karch, Annika"],["dc.contributor.author","Koch, Armin"],["dc.contributor.author","Zapf, Antonia"],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Karch, Andre"],["dc.date.accessioned","2018-11-07T10:07:22Z"],["dc.date.available","2018-11-07T10:07:22Z"],["dc.date.issued","2016"],["dc.description.abstract","Objective: To investigate how choice of gold standard biases estimates of sensitivity and specificity in studies reassessing the diagnostic accuracy of biomarkers that are already part of a lifetime composite gold standard (CGS). Study Design and Setting: We performed a simulation study based on the real-life example of the biomarker \"protein 14-3-3\" used for diagnosing Creutzfeldt Jakob disease. Three different types of gold standard were compared: perfect gold standard \"autopsy\" (available in a small fraction only; prone to partial verification bias), lifetime CGS (including the biomarker under investigation; prone to incorporation bias), and \"best available\" gold standard (autopsy if available, otherwise CGS). Results: Sensitivity was unbiased when comparing 14-3-3 with autopsy but overestimated when using CGS or \"best available\" gold standard. Specificity of 14-3-3 was underestimated in scenarios comparing 14-3-3 with autopsy (up to 24%). In contrast, overestimation (up to 20%) was observed for specificity compared with CGS; this could be reduced to 0-10% when using the \"best available\" gold standard. Conclusion: Choice of gold standard affects considerably estimates of diagnostic accuracy. Using the \"best available\" gold standard (autopsy where available, otherwise CGS) leads to valid estimates of specificity, whereas sensitivity is estimated best when tested against autopsy alone. (C) 2016 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.jclinepi.2016.03.022"],["dc.identifier.isi","000389615400010"],["dc.identifier.pmid","27107877"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39262"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1878-5921"],["dc.relation.issn","0895-4356"],["dc.title","Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","423"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Stroke"],["dc.bibliographiccitation.lastpage","429"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Schnieder, Marlena"],["dc.contributor.author","Siddiqui, Tariq"],["dc.contributor.author","Karch, André"],["dc.contributor.author","Bähr, Mathias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schroeter, Marco R"],["dc.contributor.author","Liman, Jan"],["dc.date.accessioned","2020-12-10T18:38:36Z"],["dc.date.available","2020-12-10T18:38:36Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1177/1747493018816511"],["dc.identifier.eissn","1747-4949"],["dc.identifier.issn","1747-4930"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77384"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Low flow in the left atrial appendage assessed by transesophageal echocardiography is associated with increased stroke severity—Results of a single-center cross-sectional study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2189"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Molecular Neurobiology"],["dc.bibliographiccitation.lastpage","2199"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Ebert, Elisabeth"],["dc.contributor.author","Stoeck, Katharina"],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Collins, Steven J."],["dc.contributor.author","Calero, Miguel"],["dc.contributor.author","Sklaviadis, Theodor"],["dc.contributor.author","Laplanche, Jean-Louis"],["dc.contributor.author","Golanska, Ewa"],["dc.contributor.author","Baldeiras, Ines"],["dc.contributor.author","Satoh, Katsuya"],["dc.contributor.author","Sanchez-Valle, Raquel"],["dc.contributor.author","Ladogana, Anna"],["dc.contributor.author","Skinningsrud, Anders"],["dc.contributor.author","Hammarin, Anna-Lena"],["dc.contributor.author","Mitrova, Eva"],["dc.contributor.author","Llorens, Franc"],["dc.contributor.author","Kim, Yong Sun"],["dc.contributor.author","Green, Alison"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:15:19Z"],["dc.date.available","2018-11-07T10:15:19Z"],["dc.date.issued","2016"],["dc.description.abstract","At present, the testing of 14-3-3 protein in cerebrospinal fluid (CSF) is a standard biomarker test in suspected sporadic Creutzfeldt-Jakob disease (sCJD) diagnosis. Increasing 14-3-3 test referrals in CJD reference laboratories in the last years have led to an urgent need to improve established 14-3-3 test methods. The main result of our study was the validation of a commercially available 14-3-3 ELISA next to the commonly used Western blot method as a high-throughput screening test. Hereby, 14-3-3 protein expression was quantitatively analyzed in CSF of 231 sCJD and 2035 control patients. We obtained excellent sensitivity/specificity values of 88 and 96 % that are comparable to the established Western blot method. Since standard protocols and preanalytical sample handling have become more important in routine diagnostic, we investigated in a further step the reproducibility and stability of 14-3-3 as a biomarker for human prion diseases. Ring trial data from 2009 to 2013 revealed an increase of Fleiss' kappa from 0.51 to 0.68 indicating an improving reliability of 14-3-3 protein detection. The stability of 14-3-3 protein under short-term and long-term storage conditions at various temperatures and after repeated freezing/thawing cycles was confirmed. Contamination of CSF samples with blood appears likely to be an important factor at a concentration of more than 2500 erythrocytes/mu L. Hemolysis of erythrocytes with significant release of 14-3-3 protein started after 2 days at room temperature. We first define clear standards for the sample handling, short- and long-term storage of CSF samples as well as the handling of blood- contaminated samples which may result in artificially elevated CSF levels of 14-3-3."],["dc.identifier.doi","10.1007/s12035-015-9167-5"],["dc.identifier.isi","000373641500011"],["dc.identifier.pmid","25947081"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40787"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Humana Press Inc"],["dc.relation.issn","1559-1182"],["dc.relation.issn","0893-7648"],["dc.title","Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1182"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Stroke"],["dc.bibliographiccitation.lastpage","1189"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Sporns, Peter B."],["dc.contributor.author","Straeter, Ronald"],["dc.contributor.author","Minnerup, Jens"],["dc.contributor.author","Wiendl, Heinz"],["dc.contributor.author","Hanning, Uta"],["dc.contributor.author","Chapot, René"],["dc.contributor.author","Henkes, Hans"],["dc.contributor.author","Henkes, Elina"],["dc.contributor.author","Grams, Astrid"],["dc.contributor.author","Dorn, Franziska"],["dc.contributor.author","Nikoubashman, Omid"],["dc.contributor.author","Wiesmann, Martin"],["dc.contributor.author","Bier, Georg"],["dc.contributor.author","Weber, Anushe"],["dc.contributor.author","Broocks, Gabriel"],["dc.contributor.author","Fiehler, Jens"],["dc.contributor.author","Brehm, Alex"],["dc.contributor.author","Psychogios, Marios"],["dc.contributor.author","Kaiser, Daniel"],["dc.contributor.author","Yilmaz, Umut"],["dc.contributor.author","Morotti, Andrea"],["dc.contributor.author","Marik, Wolfgang"],["dc.contributor.author","Nolz, Richard"],["dc.contributor.author","Jensen-Kondering, Ulf"],["dc.contributor.author","Schmitz, Bernd"],["dc.contributor.author","Schob, Stefan"],["dc.contributor.author","Beuing, Oliver"],["dc.contributor.author","Goetz, Friedrich"],["dc.contributor.author","Trenkler, Johannes"],["dc.contributor.author","Turowski, Bernd"],["dc.contributor.author","Möhlenbruch, Markus"],["dc.contributor.author","Wendl, Christina"],["dc.contributor.author","Schramm, Peter"],["dc.contributor.author","Musolino, Patricia"],["dc.contributor.author","Lee, Sarah"],["dc.contributor.author","Schlamann, Marc"],["dc.contributor.author","Radbruch, Alexander"],["dc.contributor.author","Rübsamen, Nicole"],["dc.contributor.author","Karch, André"],["dc.contributor.author","Heindel, Walter"],["dc.contributor.author","Wildgruber, Moritz"],["dc.contributor.author","Kemmling, André"],["dc.date.accessioned","2020-12-10T18:38:10Z"],["dc.date.available","2020-12-10T18:38:10Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1161/STROKEAHA.119.028221"],["dc.identifier.eissn","1524-4628"],["dc.identifier.issn","0039-2499"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77204"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Does Device Selection Impact Recanalization Rate and Neurological Outcome?"],["dc.title.alternative","An Analysis of the Save ChildS Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","71"],["dc.bibliographiccitation.issue","1-2"],["dc.bibliographiccitation.journal","Dementia and Geriatric Cognitive Disorders"],["dc.bibliographiccitation.lastpage","80"],["dc.bibliographiccitation.volume","43"],["dc.contributor.author","Llorens, Franc"],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Golanska, Ewa"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Lange, Peter"],["dc.contributor.author","Sikorska, Beata"],["dc.contributor.author","Liberski, Pawel P."],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:28:45Z"],["dc.date.available","2018-11-07T10:28:45Z"],["dc.date.issued","2017"],["dc.description.abstract","Background: Several biomarkers have been proposed to discriminate sporadic Creutzfeldt-Jakob disease (sCJD) from other dementias and control cases. However, their clinical accuracy depends on the PRNP codon 129 genotype, leaving it unclear how well established markers behave in untested conditions. Methods: We analyzed 14-3-3, tau, p-tau levels, and the p-tau/ tau ratio in a population sample collected from Polish hospitals including nondementia, dementia, and definite sCJD cases and validated their parameters according to previously established cutoffs. Additionally, the correlation between biomarkers and disease duration as well as the influence of the PRNP129 polymorphism are reported. Results: The tau levels and p-tau/tau ratios differed considerably between sCJD and clinically characterized non-CJD cases (p < 0.001). p-tau was only elevated in sCJD when compared to cases without dementia (p < 0.05). Tau and the p-tau/tau ratio showed a sensitivity of 95 and 100%, respectively, in detecting sCJD cases. A negative correlation between tau levels and disease duration, but not the timing of lumbar puncture was observed. Conclusion: The present findings confirmed the value of the p-tau/tau ratio as a robust sCJD biomarker and suggest a role for tau as prognostic marker. (C) 2017 S. Karger AG, Basel."],["dc.identifier.doi","10.1159/000454802"],["dc.identifier.isi","000395664800007"],["dc.identifier.pmid","28056460"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43497"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Karger"],["dc.relation.issn","1421-9824"],["dc.relation.issn","1420-8008"],["dc.title","Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Schmidt, Christian D."],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Korth, Carsten"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T09:03:55Z"],["dc.date.available","2018-11-07T09:03:55Z"],["dc.date.issued","2012"],["dc.description.abstract","Results from recent experiments with rodents imply that Alzheimer disease might be inducible by seeding A beta peptides into recipient animals. In respect to this new experimental data, public health aspects as well as epidemiological data have to be reevaluated. In this article, the available experimental and epidemiological data are reviewed."],["dc.identifier.doi","10.4161/pri.22502"],["dc.identifier.isi","000311341100008"],["dc.identifier.pmid","23052009"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10653"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24999"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Landes Bioscience"],["dc.relation.issn","1933-6896"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","On the issue of transmissibility of Alzheimer disease A critical review"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","396"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Molecular Neurobiology"],["dc.bibliographiccitation.lastpage","405"],["dc.bibliographiccitation.volume","51"],["dc.contributor.author","Cramm, Maria"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Karch, Andre"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Varges, Daniel. A."],["dc.contributor.author","Mitrova, Eva"],["dc.contributor.author","Schroeder, Bjoern"],["dc.contributor.author","Raeber, Alex"],["dc.contributor.author","Kuhn, Franziska"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:01:38Z"],["dc.date.available","2018-11-07T10:01:38Z"],["dc.date.issued","2015"],["dc.description.abstract","The development of in vitro amplification systems allows detecting femtomolar amounts of prion protein scrapie (PrPSc) in human cerebrospinal fluid (CSF). We performed a CSF study to determine the effects of prion disease type, codon 129 genotype, PrPSc type, and other disease-related factors on the real-time quaking-induced conversion (RT-QuIC) response. We analyzed times to 10,000 relative fluorescence units, areas under the curve and the signal maximum of RT-QuIC response as seeding parameters of interest. Interestingly, type of prion disease (sporadic vs. genetic) and the PRNP mutation (E200K vs. V210I and FFI), codon 129 genotype, and PrPSc type affected RT-QuIC response. In genetic forms, type of mutation showed the strongest effect on the observed outcome variables. In sporadic CJD, MM1 patients displayed a higher RT-QuIC signal maximum compared to MV1 and VV1. Age and gender were not associated with RT-QuIC signal, but patients with a short disease course showed a higher seeding efficiency of the RT-QuIC response. This study demonstrated that PrPSc characteristics in the CSF of human prion disease patients are associated with disease subtypes and rate of decline as defined by disease duration."],["dc.identifier.doi","10.1007/s12035-014-8709-6"],["dc.identifier.isi","000349006200031"],["dc.identifier.pmid","24809690"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/10255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38062"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Humana Press Inc"],["dc.relation.issn","1559-1182"],["dc.relation.issn","0893-7648"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Characteristic CSF Prion Seeding Efficiency in Humans with Prion Diseases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","93"],["dc.bibliographiccitation.journal","BMC Medical Research Methodology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Zapf, Antonia"],["dc.contributor.author","Castell, Stefanie"],["dc.contributor.author","Morawietz, Lars"],["dc.contributor.author","Karch, Andre"],["dc.date.accessioned","2018-11-07T10:10:18Z"],["dc.date.available","2018-11-07T10:10:18Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Reliability of measurements is a prerequisite of medical research. For nominal data, Fleiss' kappa (in the following labelled as Fleiss' K) and Krippendorff's alpha provide the highest flexibility of the available reliability measures with respect to number of raters and categories. Our aim was to investigate which measures and which confidence intervals provide the best statistical properties for the assessment of inter-rater reliability in different situations. Methods: We performed a large simulation study to investigate the precision of the estimates for Fleiss' K and Krippendorff's alpha and to determine the empirical coverage probability of the corresponding confidence intervals (asymptotic for Fleiss' K and bootstrap for both measures). Furthermore, we compared measures and confidence intervals in a real world case study. Results: Point estimates of Fleiss' K and Krippendorff's alpha did not differ from each other in all scenarios. In the case of missing data (completely at random), Krippendorff's alpha provided stable estimates, while the complete case analysis approach for Fleiss' K led to biased estimates. For shifted null hypotheses, the coverage probability of the asymptotic confidence interval for Fleiss' K was low, while the bootstrap confidence intervals for both measures provided a coverage probability close to the theoretical one. Conclusions: Fleiss' K and Krippendorff's alpha with bootstrap confidence intervals are equally suitable for the analysis of reliability of complete nominal data. The asymptotic confidence interval for Fleiss' K should not be used. In the case of missing data or data or higher than nominal order, Krippendorff's alpha is recommended. Together with this article, we provide an R-script for calculating Fleiss' K and Krippendorff's alpha and their corresponding bootstrap confidence intervals."],["dc.identifier.doi","10.1186/s12874-016-0200-9"],["dc.identifier.isi","000381100600001"],["dc.identifier.pmid","27495131"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13860"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39826"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2288"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Measuring inter-rater reliability for nominal data - which coefficients and confidence intervals are appropriate?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]